The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy.
Xuezhong Yang
No relevant relationships to disclose
Christina Sing-Ying Wu
No relevant relationships to disclose
Jimmy J. Hwang
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche
Expert Testimony - Roche
Benjamin Weinberg
No relevant relationships to disclose
Michael J. Pishvaian
No relevant relationships to disclose
Aiwu Ruth He
No relevant relationships to disclose
John Marshall
Consultant or Advisory Role - Genentech
Honoraria - Genentech